| Autor: |
Mihaylov, Georgi, Mihaylova, Zhasmina, Drgona, Lubos, Cipkova, Andrea, Novak, Jan, Petrova, Roumyana |
| Zdroj: |
memo - Magazine of European Medical Oncology; Sep2016, Vol. 9 Issue 3, p144-152, 9p |
| Abstrakt: |
Background: Febrile neutropenia (FN) is a common side effect of chemotherapy that frequently necessitates hospitalization and healthcare resource utilization (HCRU), but is poorly studied in Eastern European countries. We investigated HCRU and granulocyte colony-stimulating factor (G-CSF) use in patients hospitalized for FN in Bulgaria, Czech Republic, and Slovakia. Patients and methods: This was a multicenter retrospective cohort study. Eligible patients were ≥18 years old, had received chemotherapy for solid tumors or hematological malignancies of any stage, and had been hospitalized for FN. The primary objective was to evaluate FN-related HCRU; secondary objectives included the description of chemotherapy treatment patterns and G-CSF use. Data were analyzed by participating country. Results: Data of 156 patients from Bulgaria and 79 patients each from the Czech Republic and Slovakia were analyzed. The most frequent solid tumors were breast ( n = 28) and testicular cancer ( n = 13), and the most common hematological malignancies were non-Hodgkin B-cell lymphoma ( n = 51) and acute myeloid leukemia ( n = 35). In general, G-CSF was used to treat FN rather than as prophylaxis. Most patients had a single FN episode, predominantly in cycle 1. The mean duration of FN-related hospitalization was 7-9 days, with longer stays in patients with hematological malignancies. Conclusions: Results indicate considerable FN-related HCRU in all countries. Frequent lack of G-CSF primary prophylaxis was observed, particularly in Slovakia. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink